ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Thrombolytic Science Granted a Second US Patent on Its Clot Dissolving Therapy, A Novel, Nature-inspired Treatment for Ischemic Strokes B3Cnewswire
January 06, 2022Thrombolytic Science, LLC (TSI) has been granted a second patent by the USPTO. The patent was granted for a novel treatment applicable to ischemic stroke, one of the leading causes of morbidity and mortality. -
TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction b3cnewswire
October 31, 2019Thrombolytic Science, LLC?(TSI)?announced progress with 10 patients enrolled in its prospective, randomized, multicenter?Phase 2 clinical trial, designed to confirm the safety and ...
Pharma Sources Insight January 2025
